Eli Lilly Stock Analysis
2 articles on Eli Lilly Stock Analysis, written by Shotlee and medically reviewed for clinical accuracy.
Deutsche Bank Reiterates Buy on Eli Lilly Stock on GLP-1 Growth
Deutsche Bank has reiterated its Buy rating on Eli Lilly stock, highlighting robust GLP-1 prescription growth despite recent dips. With Mounjaro and Zepbound leading, prescriptions rebounded 7% week-over-week, underscoring Lilly's dominance in the diabesity market. Discover the latest data on oral Wegovy and emerging oral GLP-1s like orforglipron.
5 min read
How Eli Lilly's Mounjaro Is Transforming Obesity Treatment and the LLY Stock Narrative
Eli Lilly's Mounjaro, a groundbreaking GLP-1 agonist, is altering the landscape of obesity and diabetes management in the US. This article explores its market success, addresses key patient challenges, and delves into the investment implications for LLY stock, highlighting growth drivers and potential risks.
6 min read